# US 12,110,291 B2 · Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,110,291 B2
- Document ID: US12110291B2
- Status: Granted
- Kind: B2
- Application number: 18/524,705
- Filed: 2023-11-30
- Published: 2024-07-04
- Granted: 2024-10-08
- Earliest claimed: 2022-11-30
- Assignees: Tiger Biotherapeutics Inc.
- Applicants: Tiger Biotherapeutics Inc.
- Inventors: Robert Luo; Ji Liu; Pin Huang; Jie Su; Yan Feng; Ke Liu; Jie Fan; Wei He; Yimin Qian
- Web page: https://patentgrep.com/patent/US12110291B2

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

## Claims

### Claim 1

A compound, wherein the compound is represented by Formula IB′ or is a pharmaceutically acceptable salt thereof:
wherein:
each Rb is independently selected from halogen, hydroxy, amino, and C1-C4 alkyl;
n′ is 1 or 2;
R2 is H;
R3 is halogen;
Q is selected from
and
L is selected from

### Claim 2 (depends on 1)

The compound of claim 1, wherein Q is

### Claim 3 (depends on 1)

The compound of claim 1, wherein L is selected from

### Claim 4 (depends on 1)

The compound of claim 1, wherein L is selected from

### Claim 5 (depends on 1)

The compound of claim 1, wherein L is selected from

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is selected from

### Claim 7 (depends on 6)

The compound of claim 6, wherein R1 is selected from

### Claim 8 (depends on 7)

The compound of claim 7, wherein R1 is

### Claim 9 (depends on 7)

The compound of claim 7, wherein R1 is

### Claim 10 (depends on 1)

The compound of claim 1, wherein the compound is selected from
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 10 and one or more pharmaceutically acceptable carriers, pharmaceutically acceptable vehicles, pharmaceutically acceptable excipients, or combinations thereof.

### Claim 12 (depends on 11)

A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of at least one compound according to claim 11, wherein the cancer is selected from lung cancer, pancreatic cancer, small bowel cancer, colorectal cancer, gall bladder cancer, thyroid cancer, liver cancer, bile duct cancer, cervical cancer, bladder cancer, prostate cancer, esophageal cancer, and blood cancer.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 19 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 20 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 21 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 23 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 24 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 25 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 27 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 28 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 29 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 30 (depends on 12)

The method of claim 12, wherein the cancer is pancreatic cancer.

### Claim 31 (depends on 12)

The method of claim 12, wherein the cancer is lung cancer.

### Claim 32 (depends on 12)

The method of claim 12, wherein the cancer is colorectal cancer.